The relationship between serum tumor-associated trypsin inhibitor levels and clinicopathological parameters in patients with gastric cancer

Kemik, O.; Kemik, A.; Sumer, A.; Almalı, Necat; Gurluler, ERCÜMENT; Gures, N.; Purisa, S.; Adas, G.; Dogan, Y.; Tuzun, S.

The relationship between serum tumor-associated trypsin inhibitor levels and clinicopathological parameters in patients with gastric cancer

Copy For Citation

Kemik O., Kemik A., Sumer A., Almalı N., Gurluler E., Gures N., ...More

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, vol.17, no.21, pp.2923-2928, 2013 (SCI-Expanded)

Publication Type: Article / Article
Volume: 17 Issue: 21
Publication Date: 2013
Journal Name: EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.2923-2928
Keywords: Tumor-associated trypsin inhibitor, Clinical-pathological features, Gastric cancer, COLON-CANCER, EXPRESSION, TATI, FIBROBLASTS, ANTIGEN, URINE
Bursa Uludag University Affiliated: No

Abstract

BACKGROUND: Tumor-associated trypsin inhibitor (TATI) is expressed with trypsinogen in tumors. We studied the clinical-pathologic association and significance of preoperative serum levels of TATI in gastric cancer patients.